Catheter Precision Files S-1 for Public Offering

TL;DR

Catheter Precision (formerly Ra Medical) just filed an S-1, looks like they're prepping for a public stock offering.

AI Summary

Catheter Precision, Inc. filed an S-1 registration statement on November 21, 2024, indicating plans to offer securities. The company, formerly known as Ra Medical Systems, Inc., is incorporated in Delaware and headquartered in Fort Mill, SC. This filing is a standard step for companies looking to raise capital through public offerings.

Why It Matters

This S-1 filing signals Catheter Precision, Inc.'s intention to access public markets, potentially for funding growth, acquisitions, or other strategic initiatives.

Risk Assessment

Risk Level: medium — S-1 filings indicate a company is seeking public investment, which carries inherent market and execution risks for investors.

Key Numbers

• 3841 — SIC Code (Identifies the company's industry as Surgical & Medical Instruments & Apparatus.)
• 38-3661826 — IRS Number (Company's Employer Identification Number.)

Key Players & Entities

• Catheter Precision, Inc. (company) — Registrant
• Ra Medical Systems, Inc. (company) — Former company name
• November 21, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• Fort Mill, SC (location) — Principal executive offices
• David Jenkins (person) — Executive Chairman of the Board and Chief Executive Officer

FAQ

Key Financial Figures

• $0.0001 — " Shares ") of common stock, par value $0.0001 per share, of Catheter Precision, Inc.,
• $0.70 — ereafter, and have an exercise price of $0.70 per share, subject to adjustment. Purs
• $0.42 — rted sale price of our common stock was $0.42 per share. Investing in our securitie

Filing Documents

• rmed_s1.htm (S-1) — 583KB
• rmed_ex51.htm (EX-5.1) — 11KB
• rmed_ex231.htm (EX-23.1) — 2KB
• rmed_ex232.htm (EX-23.2) — 3KB
• rmed_ex107.htm (EX-FILING FEES) — 9KB
• rmed_ex51img1.jpg (GRAPHIC) — 5KB
• rmed_s1img2.jpg (GRAPHIC) — 4KB
• 0001654954-24-014768.txt ( ) — 621KB

RISK FACTORS

RISK FACTORS 4 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 5

USE OF PROCEEDS

USE OF PROCEEDS 6 SELLING STOCKHOLDERS 7

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 12 PLAN OF DISTRIBUTION 20 LEGAL MATTERS 21 EXPERTS 21 WHERE YOU CAN FIND ADDITIONAL INFORMATION 22 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 22 ii Table of Contents ABOUT THIS PROSPECTUS We urge you to read carefully this prospectus, together with the information incorporated herein by reference as described under the heading "Where You Can Find Additional Information," before buying any of the securities being offered. You should rely only on the information contained or incorporated by reference in this prospectus. We and the Selling Stockholders have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus may only be used where it is legal to offer and sell shares of our common stock. If it is against the law in any jurisdiction to make an offer to sell these shares, or to solicit an offer from someone to buy these shares, then this prospectus does not apply to any person in that jurisdiction, and no offer or solicitation is made by this prospectus to any such person. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock. Our business, financial condition, results of operations and prospects may have changed since such date. Information contained on our website is not a part of this prospectus. A prospectus supplement may add to, update or change the information contained in this prospectus. You should read both this prospectus and any applicable prospectus supplement together with additional information described below under the heading "Where You Can Find Additional Information." This prospectus may contain references to trademarks belonging to other entities. Solely for convenience, trademarks and tra

Use of proceeds

Use of proceeds We will not receive any proceeds from the sale of shares of common stock by the Selling Stockholders. Offering price The Selling Stockholders may sell all or a portion of their shares through public or private transactions at prevailing market prices or at privately negotiated prices. See "Plan of Distribution."

Risk factors

Risk factors You should read the "Risk Factors" section included in this prospectus, and the risk factors incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. NYSE American symbol "VTAK" The Selling Stockholders may offer and sell up to 10,695,962 shares of our common stock. Throughout this prospectus, when we refer to the shares of our common stock being registered on behalf of the Selling Stockholders for offer and resale, we are referring to the shares of common stock that may be issued upon exercise of Series K Warrants issued in the Warrant Repricing. When we refer to the Selling Stockholders in this prospectus, we are referring to the Selling Stockholder identified in this prospectus and its permitted transferees or other successors-in-interest that may be identified, to the extent required, in a supplement to this prospectus or a post-effective amendment to the registration statement of which this prospectus is a part. 3 Table of Contents

RISK FACTORS

RISK FACTORS Investing in our securities involves a high degree of risk. Before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part, you should carefully consider, in addition to the risks and uncertainties discussed under "Special Note Regarding Forward-Looking Statements" below, the risk factors set forth under "Risk Factors" in our previous SEC filings, all of which are incorporated by reference into this prospectus: our most recent Annual Report on Form 10-K, as amended, our most recent Quarterly Reports on Form 10-Q filed subsequent to such filing, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. The Risk Factors set forth in the filings described above may be amended, supplemented or superseded from time to time by other reports and/or prospectus supplements we file with the SEC in the future, and you should carefully consider any such additional or modified risk factors and other information provided in any such future filings that may be available after the date of this prospectus before making your investment decision. If any of the risks set forth in the filings described above actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and/or the available secondary market for our securities may diminish or become non-existent, and you could lose all or part of your investment or lose liquidity in the shares. The risks and uncertainties we describe in the documents incorporated by reference herein are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial could materially adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in

USE OF PROCEEDS

USE OF PROCEEDS We are filing the registration statement of which this prospectus is a part to permit holders of the shares of our common stock described in the section entitled "Selling Stockholders" to resell such shares. We are not selling any securities under this prospectus and we will not receive any proceeds from the sale or other disposition of shares of our common stock held by the Selling Stockholders. The Selling Stockholders will receive all of the proceeds from this offering. The Selling Stockholders will pay any discounts, commissions, fees of underwriters, selling brokers or dealer managers and expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration and filing fees, printing fees, NYSE American listing fees and fees and expenses of our counsel and our accountants, including our independent registered public accounting firms. 6 Table of Contents SELLING STOCKHOLDERS This prospectus covers the resale or other disposition of up to 10,695,962 Shares by the Selling Stockholders named below that may be acquired upon exercise of our Series K Warrants, and their donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer (collectively, the "Selling Stockholders"). Our Series K Warrants are not currently exercisable and may not be exercised until stockholder approval of the exercise has been obtained. We currently intend to seek such stockholder approval at a special meeting to be held on January 13, 2025. The table below sets forth, to our knowledge,

View Full Filing

View this S-1 filing on SEC EDGAR